INGN Stock Gains Post Latest Launch to Expand Respiratory Care Suite

Inogen, Inc. INGN has launched Aurora CPAP (continuous positive airway pressure) masks for Obstructive Sleep Apnea (OSA) in the United States yesterday. The FDA 510(k)-cleared mask is a new product within the company’s expanding portfolio.

Per INGN, the Aurora Mask portfolio — which includes the F1 Full Face, N1 Nasal Cushion and P1 Nasal Pillows — has been specifically designed to meet the diverse needs of most patients using CPAP devices. Aurora Masks provide options for different facial structures and therapy needs, promoting patient-focused care and encouraging consistent use in sleep and respiratory therapy.

The latest offering is expected to significantly boost Inogen’s respiratory care portfolio and strengthen its foothold in the OSA space.

Trend in INGN Stock Following the News

Following the announcement, shares of the company gained nearly 7.8% till yesterday’s close.

Historically, the company has gained a top-line boost from its various product innovations and launches. We expect market sentiment for the stock to remain positive around this announcement, too.

Inogen currently has a market capitalization of $198.7 million. It has a price-to-sales ratio (P/S) of 0.6 compared with the industry’s 3.9. In the last reported quarter, INGN delivered an earnings surprise of 9.1%.

Significance of Inogen’s Latest Offering

Per Inogen, Aurora Masks are expected to establish the company’s presence in the growing sleep-therapy market and expand its addressable market opportunity. The company intends to leverage its existing distribution channels and partnerships to bring Aurora CPAP masks to customers and strengthen relationships with providers.

Management believes that the launch of Aurora CPAP masks is a pivotal step for Inogen toward expanding into a broad home care respiratory solutions company and its entry into the sleep apnea market.

Industry Prospects in Favor of INGN

Per a report by Grand View Research, the global sleep apnea devices market was estimated at $4.5 billion in 2023 and is anticipated to reach $6.9 billion by 2030 at a CAGR of 6.2%. Factors like technological advancements and the growing elderly population's vulnerability to sleep apnea are likely to drive the market.

Given the market potential, the latest launch is expected to provide a significant boost to Inogen’s business.

Inogen’s Notable Launches

In November 2025, Inogen announced third-quarter 2025 results, wherein it confirmed that it initiated a limited market release of the Simeox airway clearance device in the United States.

In June, Inogen announced the launch of Voxi 5, a new stationary oxygen concentrator designed to enhance access to high-quality oxygen therapy for long-term care patients in the United States.

INGN’s Share Price Performance

Shares of the company have lost 24.6% in the past year against the industry’s 4.4% rise and the S&P 500’s gain of 19.3%.

Inogen’s Zacks Rank & Key Picks

Currently, INGN carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Boston Scientific Corporation BSX, Cardinal Health, Inc. CAH and IDEXX Laboratories, Inc. IDXX.

Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 16.4%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Boston Scientific’s shares have gained 2.8% against the industry’s 3.2% decline in the past year.

Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.9%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 9.4%.

Cardinal Health has rallied 69.1% compared with the industry’s 11.1% growth in the past year.

IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.1%.

IDEXX’s shares have gained 65.3% compared with the industry’s 4.4% growth in the past year.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research